Y.D. More Investments’s Protalix BioTherapeutics PLX Stock Holding History

Y.D. More Investments’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$477	Hold	220	–	–	﹤0.01%	424
2025 Q4	$383	Hold	220	–	–	﹤0.01%	427
2025 Q3	$488	Hold	220	–	–	﹤0.01%	402
2025 Q2	$325	Hold	220	–	–	﹤0.01%	409
2025 Q1	$563	Hold	220	–	–	﹤0.01%	417
2024 Q4	$414	Hold	220	–	–	﹤0.01%	404
2024 Q3	$224	Hold	220	–	–	﹤0.01%	389
2024 Q2	$257	Buy	+220	New	+$260	﹤0.01%	396

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Y.D. More Investments's PLX Position: Q1 2026 in Review

Y.D. More Investments held its Protalix BioTherapeutics (PLX) position steady in Q1 2026 at 220 shares worth $477. The position accounts for ﹤0.01% of the portfolio, ranked #424.

Y.D. More Investments first reported a position in PLX in Q2 2024 and has held it in 8 quarters since. The position peaked at $563 in Q1 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

Y.D. More Investments held 220 shares of Protalix BioTherapeutics worth $477 as of Q1 2026.
Y.D. More Investments left its Protalix BioTherapeutics share count unchanged in Q1 2026.
Protalix BioTherapeutics made up ﹤0.01% of Y.D. More Investments's portfolio in Q1 2026, its #424 holding.
Y.D. More Investments first reported a position in Protalix BioTherapeutics in Q2 2024 and has held it in 8 quarters since.
Y.D. More Investments's Protalix BioTherapeutics position peaked at $563 in Q1 2025.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Y.D. More Investments's 13F filing for Q1 2026, filed 4 May 2026.